Anti-HIV-1/HIV-2 protease Purified

Anti-HIV-1/HIV-2 protease Purified

• CAS Number: 9007-83-4
• Clone: 1696
• Format: Purified
• Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• References & Citations: *O'Loughlin TL, Greene DN, Matsumura I: Diversification and specialization of HIV protease function during in vitro evolution. Mol Biol Evol. 2006 Apr23(4):764-72., URL: https://www.ncbi.nlm.nih.gov/pubmed/16423863?dopt=,*Bartonová V, Král V, Sieglová I, Brynda J, Fábry M, Horejsí M, Kozísek M, Sasková KG, Konvalinka J, Sedlácek J, Rezácová P: Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. Antiviral Res. 2008 Jun78(3):275-7. Epub 2008 Feb 20., URL: https://www.ncbi.nlm.nih.gov/pubmed/18329737?ordin,*Lescar J, Brynda J, Rezacova P, Stouracova R, Riottot MM, Chitarra V, Fabry M, Horejsi M, Sedlacek J, Bentley GA: Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody. Protein Sci. 1999 Dec8(12):2686-96., URL: https://www.ncbi.nlm.nih.gov/pubmed/10631984?dopt=,
• Other References: *Kovalevsky AY, Chumanevich AA, Liu F, Louis JM, Weber IT: Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. Biochemistry. 2007 Dec 2546(51):14854-64., URL: https://www.ncbi.nlm.nih.gov/pubmed/18052235?ordin,*Lapins M, Eklund M, Spjuth O, Prusis P, Wikberg JE: Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics. 2008 Apr 109(1):181, URL: https://www.ncbi.nlm.nih.gov/pubmed/18402661?ordin,*Brower ET, Bacha UM, Kawasaki Y, Freire E: Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008 Apr71(4):298-305., URL: https://www.ncbi.nlm.nih.gov/pubmed/18312292?ordin,*Velazquez-Campoy A, Todd MJ, Vega S, Freire E: Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001 May 2298(11):6062-7., URL: https://www.ncbi.nlm.nih.gov/pubmed/11353856?ordin,